Protein delivery by secretory gland expression

• US 6,004,944 A
• Filed: 10/02/1997
• Issued: 12/21/1999
• Est. Priority Date: 03/24/1995
• Status: Expired due to Fees

• Current Assignee: Regents of the University of California (University of California)
• Original Assignee: Regents of the University of California (University of California)
• Inventors: German, Michael S., Rothman, Stephen S., Goldfine, Ira D.
• Primary Examiner(s): Priebe, Scott D.
• Assistant Examiner(s): Nguyen, Dave Trong
• Application Number:
  US08/942,939
• Time in Patent Office: 810 Days
• Field of Search: 514/44, 424/93.21, 435/325, 435/320.1, 435/455, 435/458, 536/23.1
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 38/27 Growth hormone [GH], i.e. somatotropin
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 38/37 Factors VIII
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 5/48 of the pancreatic hormones

Abstract

Secretory gland cells, particularly pancreatic, hepatic, and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the bloodstream to obtain therapeutic levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term or short term therapies for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.

Claims

1. A method of reducing blood glucose levels in a diabetic mammalian subject, the method comprising:

introducing into the pancreas of the mammalian subject a construct comprising an insulin-encoding DNA and a promoter sequence operably linked to the insulin-encoding DNA to facilitate expression in a eukaryotic cell, said introducing being by intraductal administration;

wherein expression of the introduced construct in the pancreas occurs such that a biologically active insulin polypeptide is delivered into the bloodstream of the patient in a therapeutically effective amount, and blood glucose levels in the mammalian subject are reduced.

2. The method of claim 1, wherein a euglycemic state is maintained for at least three days.

3. The method of claim 1, wherein a euglycemic state is maintained for at least 6 days.

4. The method of claim 1, the method further comprising enhancing delivery of the insulin polypeptide to the bloodstream by administration of a cholinergic agonist to the mammalian subject.

5. The method of claim 1, the method further comprising enhancing delivery of the insulin polypeptide into the bloodstream by ingestion of a meal by the mammalian subject.

6. A method of delivering a desired polypeptide to a mammalian subject, the method comprising:

introducing in vivo into a lumen of a duct of a salivary gland and into a lumen of a duct of a liver of the mammalian subject a construct comprising a DNA of interest that encodes the desired polypeptide and a promoter sequence operably linked to the DNA of interest to facilitate expression in a eukaryotic cell;

wherein the introduced construct is expressed in each of the salivary gland and the liver such that the polypeptide is delivered into the bloodstream of the mammal from each of the salivary gland and the liver.

7. The method of claim 6, wherein the DNA of interest encodes a factor VIII polypeptide.

8. The method of claim 6, wherein the DNA of interest encodes a erythropoietin polypeptide.

9. The method of claim 6, wherein introduction into the salivary gland and into the liver is by retrograde ductal administration.

10. The method of claim 6, wherein the construct introduced into the salivary gland is not contained within a viral particle.

30. The method of claim 6, wherein the desired polypeptide is selected from the group consisting of insulin, growth hormone, interferon-alpha 2b, Interferon-alpha 2a, interferon-alpha N1, filgastim, insulinotropin, imiglucerase, clotting factor VIII, interferon-beta1b, erythropoietin, sargramostim, interleukin-2, interferon-gamma, anti-CD3 antibody, GPIIb/IIIa monoclonal antibody, adenosine deaminase, interleukin-8, insulin-like growth factor-1, platelet-derived growth factor, epidermal growth factor, and hemoglobin.

31. The method of claim 6, wherein the DNA of interest encodes a human insulin polypeptide.

11. A method of delivering a polypeptide to a mammalian subject, the method comprising:

introducing in vivo into a lumen of a duct of a salivary gland and into a lumen of a duct of a pancreas of the mammalian subject a construct comprising a DNA of interest that encodes a desired polypeptide and a promoter sequence operably linked to the DNA of interest to facilitate expression in a eukaryotic cell;

wherein the introduced construct is expressed in each of the salivary gland and the pancreas such that the polypeptide is delivered into the bloodstream of the mammalian subject from each of the salivary gland and the pancreas.

12. The method of claim 11, wherein the desired polypeptide is selected from the group consisting of insulin, growth hormone, interferon-alpha 2b, Interferon-alpha 2a, interferon-alpha N1, filgastim, insulinotropin, imiglucerase, clotting factor VIII, interferon-beta1b, erythropoietin, sargramostim, interleukin-2, interferon-gamma, anti-CD3 antibody, GPIIb/IIIa monoclonal antibody, adenosine deaminase, interleukin-8, insulin-like growth factor-1, platelet-derived growth factor, epidermal growth factor, and hemoglobin.

13. The method of claim 11, wherein the DNA of interest encodes a human insulin polypeptide.

14. The method of claim 11, wherein the DNA of interest encodes a factor VIII polypeptide.

15. The method of claim 11, wherein the DNA of interest encodes a crythropoietin polypeptide.

16. The method of claim 11, wherein introduction into the salivary gland and into the pancreas is by retrograde ductal administration.

17. The method of claim 11, wherein the construct introduced into the salivary gland is not contained within a viral particle.

18. A method of delivering a polypeptide to a mammalian subject, the method comprising:

administering directly in vivo into a lumen of a duct of a pancreas and into a lumen of a duct of a liver of the mammalian subject a construct comprising a DNA of interest that encodes a desired polypeptide and a promoter sequence operably linked to the DNA of interest to facilitate expression in a eukaryotic cell;

wherein the introduced construct is expressed in each of the pancreas and the liver such that the polypeptide is delivered into the bloodstream of the mammal from each of the pancreas and the liver.

19. The method of claim 18, wherein the desired polypeptide is selected from the group consisting of insulin, growth hormone, interferon-alpha 2b, Interferon-alpha 2a, interferon-alpha N1, filgastim, insulinotropin, imiglucerase, clotting factor VIII, interferon-beta1b, erythropoietin, sargramostim, interleukin-2, interferon-gamma, anti-CD3 antibody, GPIIb/IIIa monoclonal antibody, adenosine deaminase, interleukin-8, insulin-like growth factor-1, platelet-derived growth factor, epidermal growth factor, and hemoglobin.

20. The method of claim 18, wherein the DNA of interest encodes a human insulin polypeptide.

21. The method of claim 18, wherein the DNA of interest encodes a factor VIII polypeptide.

22. The method of claim 18, wherein the DNA of interest encodes an crythropoietin polypeptide.

23. The method of claim 18, wherein said administering is by retrograde ductal administration.

24. The method of claim 18, wherein said administering is by injection.

25. The method of claim 18, wherein said administering is by cannulation.

26. The method of claim 25, wherein said cannulation is by inserting a cannula through a lumen of the gastrointestinal tract.

27. The method of claim 25, wherein said cannulation is through an external orifice.

28. The method of claim 25, wherein said cannulation is by inserting a cannula through a common bile duct, wherein the DNA construct is delivered directly into the hepatic duct and into the pancreatic duct.

29. The method of claim 18, wherein the introduced construct is expressed in each of the pancreas and the liver such that the level of polypeptide in pancreatic tissue is elevated relative to a level of polypeptide in pancreatic tissue after delivery of the same amount of the construct in the same manner to pancreas alone.